(S (NP-SBJ (NP Direct/JJ exposure/NN) (PP to/TO (NP (NP 2,3,7,8-tetrachlorodibenzo-p-dioxin/NN) (PRN -LRB-/-LRB- (NP TCDD/NN) -RRB-/-RRB-)))) (VP increases/VBZ (NP (NP infectivity/NN) (PP of/IN (NP human/JJ erythrocytes/NNS)) (PP to/TO (NP a/DT malarial/JJ parasite/NN)))) ./.)
(S (NP-SBJ (NP Direct/JJ exposure/NN) (PP to/TO (NP (ADJP 10/CD nM/NN) 2,3,7,8-TCDD/NN))) (VP caused/VBD (NP (NP-COOD (NP a/DT 75/CD %/NN increase/NN) and/CC (NP a/DT (QP 2-fold/JJ) increase/NN)) (PP in/IN (NP (NP the/DT infectivity/NN) (PP of/IN (NP isolated/VBN human/JJ erythrocytes/NNS)) (PP to/TO (NP P./FW falciparum/FW))))) (PP-TMP after/IN (NP (NP 48/CD hours/NNS) (SBAR (WHADVP-16 when/WRB) (S (NP-SBJ the/DT parasites/NNS) (VP were/VBD (PP-PRD in/IN (NP (NP an/DT (ADJP-COOD (ADJP unsynchronized/JJ) or/CC (ADJP synchronized/JJ)) state/NN) (PP of/IN (NP growth/NN)))) ,/, (ADVP respectively/RB) (ADVP *T*-16/-NONE-))))))) ./.)
(S (NP-SBJ (NP Treatment/NN) (PP of/IN (NP human/JJ erythrocytes/NNS)) (PP with/IN (NP (NP (ADJP 10/CD microM/NN) (NP (NP sodium/NN orthovanadate/NN) (PRN -LRB-/-LRB- (NP NaOV/NN) -RRB-/-RRB-))) ,/, (NP (NP an/DT inhibitor/NN) (PP of/IN (NP-COOD (NP plasma/NN membrane/NN Ca-ATPase/NN) and/CC (NP phosphotyrosine/NN phosphatase/NN)))) ,/,))) (VP decreased/VBD (NP parasitemia/NN) (PP by/IN (NP 30/CD %/NN))) ./.)
(S (NP-SBJ (NP Co-treatment/NN) (PP of/IN (NP RBCs/NNS)) (PP with/IN (NP-COOD (NP TCDD/NN) and/CC (NP NaOV/NN)))) (ADVP completely/RB) (VP blocked/VBD (NP (NP the/DT TCDD-induced/JJ increase/NN) (PP in/IN (NP parasitemia/NN)))) ./.)
(S (SBAR Because/IN (S (NP-SBJ-17 erythrocytes/NNS) (VP are/VBP (VP anucleated/JJ (NP *-17/-NONE-))))) ,/, (NP-SBJ-18 these/DT results/NNS) (VP are/VBP (VP discussed/VBN (NP *-18/-NONE-) (PP as/IN (NP (NP evidence/NN) (PP for/IN (NP (NP biochemical/JJ changes/NNS) (PP by/IN (NP TCDD/NN)) (PP without/IN (S (NP-SBJ */-NONE-) (VP requiring/VBG (NP (NP the/DT activation/NN) (PP of/IN (NP gene/NN products/NNS)))))))))))) ./.)
